6-K ·Filed Jun 15, 2026

GMAB

GENMAB A/S
NEUTRAL
Impact 2/10
Horizonmonths Processed3mo ago SEC0001434265-26-000090
Notable filing: 6-K
Actionable Insight • Neutral

This filing is purely administrative with no trading implications. Monitor for any future capital increases or warrant exercises, but the current filing does not alter the company's financial outlook or operations.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d ⚠ clustered
GMAB ▲ +34.42% at T+60d
NEUTRAL call ✓ call won +34.42% · α vs SPY +33.42% · entry $24.58 → $33.04
Entry anchored
Jun 15, 11:07 AM ET
via exchange tick
T+1d
+0.65%
call +0.65% · α +1.25%
$24.74
settled 4mo ago
T+5d
+4.19%
call +4.19% · α +5.57%
$25.61
settled 3mo ago
T+20d
+17.17%
call +17.17% · α +17.92%
$28.80
settled 3mo ago
T+60d
+34.42%
call +34.42% · α +33.42%
$33.04
settled 22d ago

Price Chart

Loading chart...

Executive Summary

Genmab A/S filed its updated Articles of Association via a 6-K on June 15, 2026, reflecting standard corporate governance provisions including share capital details, authorized capital increases, employee warrant programs, and a board indemnification scheme. This is a routine administrative filing with no financial results, material events, or strategic announcements.

Key Facts

  • Share capital is DKK 62,353,067 divided into shares of DKK 1 each.
  • Board authorized until March 12, 2029 to increase share capital by up to DKK 6,600,000 (with or without pre-emption rights).
  • Multiple warrant programs for employees (excluding executive management) with up to DKK 750,000 nominal each, expiring between 2026 and 2030.
  • Board authorized to issue convertible debt instruments up to DKK 3,000,000 nominal until March 12, 2029.
  • Indemnification scheme for board members established through March 12, 2029.

Financial Impact

No material financial impact; routine governance update.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (25 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001434265-26-000090
Document: gmab_20260615xx6k.htm0001434265-26-000090
Document: 0001434265-26-000090-index-headers.html0001434265-26-000090
Document: 0001434265-26-000090-index.html0001434265-26-000090
Document: 0001434265-26-000090.txt0001434265-26-000090
13 reports for GMAB
Performance horizon
75% Hit rate 3 of 4 directional calls best @ T+60▲ +26.50%Jun 29, 2026
Filters
Rows
Reports for GMAB — sortable, filterable
TypeNow
Sep 8, 2026
24d ago
6-K
NEUTRAL ★ 2/10
$33.53 $32.65▼ −2.62%▼ −1.96%$34.51 (+2.94%)
Aug 12, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$31.42 $34.11▲ +8.56%▲ +9.01%$34.51 (+9.85%)
Aug 11, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$30.85 $32.96▲ +6.84%▲ +7.24%$34.51 (+11.88%)
Aug 6, 2026
8w ago
6-K
BULLISH ★ 6/10
$29.83 $31.34▲ +5.06%▲ +3.85%$34.51 (+15.71%)
Jul 15, 2026
11w ago
6-K
NEUTRAL ★ 3/10
$29.08 $28.85▼ −0.79%▲ +0.19%$34.51 (+18.69%)
Jun 29, 2026
13w ago
6-K
BULLISH ★ 7/10
$27.47 $28.01▲ +1.97%▲ +1.36%$34.51 (+25.65%)
Jun 17, 2026
15w ago
6-K
NEUTRAL ★ 2/10
$25.39 $25.87▲ +1.87%▲ +2.91%$34.51 (+35.94%)
Jun 16, 2026
15w ago
6-K
NEUTRAL ★ 1/10
$24.74 $25.94▲ +4.85%▲ +7.08%$34.51 (+39.51%)
Jun 15, 2026
15w ago
6-K
NEUTRAL ★ 2/10
$24.58 $25.61▲ +4.19%▲ +5.57%$34.51 (+40.42%)
Jun 15, 2026
15w ago
6-K
NEUTRAL ★ 2/10
$24.58 $25.61▲ +4.19%▲ +5.57%$34.51 (+40.42%)
Showing 10 of 13

US Market Status

Market Open — Closes in 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access